预约演示
更新于：2025-07-08
Pantoprazole Sodium Hydrate
泮托拉唑钠
更新于：2025-07-08
概要
基本信息
简介安托拉唑是一种小分子药物，被归类为质子泵抑制剂，这意味着它可以减少胃中产生的酸量。 Takeda Pharmaceutical Co., Ltd. 于 1994 年 1 月首次批准该药物。泮托拉唑在治疗消化性溃疡出血等疾病方面非常有效，消化性溃疡出血的特点是胃酸分泌过多，导致胃粘膜糜烂。当酸分泌会引起疼痛和出血时，它也可用于治疗禁食。一般来说，泮托拉唑耐受性良好且不良反应极小，使其成为酸相关疾病的常见治疗选择。 |
药物类型 小分子化药 |
别名 Anagastra、Controloc、Eupantol + [51] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H17F2N3NaO5S |
InChIKeyRJRBTVMZZGMTQI-UHFFFAOYSA-N |
CAS号164579-32-2 |
关联
270
项与 泮托拉唑钠 相关的临床试验NCT06706258
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial): A Prospective Randomized Controlled Trial
IRCT20241017063400N1
Evaluation of the effectiveness of proton pump inhibitors (intravenous pantoprazole) in controlling vomiting in patients with acute gastroenteritis compared to fluid therapy and NPO
IRCT20200623047902N7
Bioequivalence study of Pantoprazole 40 mg tablet manufactured by Sanamed company versus the originator brand in fed and fast condition in healthy volunteers
100 项与 泮托拉唑钠 相关的临床结果
登录后查看更多信息
100 项与 泮托拉唑钠 相关的转化医学
登录后查看更多信息
100 项与 泮托拉唑钠 相关的专利（医药）
登录后查看更多信息
4,774
项与 泮托拉唑钠 相关的文献（医药）2025-08-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Static and in-situ synchrotron X-ray microtomography analysis of pharmaceutical tablets
Article
作者: Küstner, Bernd ; Seim, Christian ; Westenberger, Peter ; Mattern, Enni ; Müller, Lena ; Doucet, Jean ; Hesse, Bernhard ; Schweitzer, Luiz ; Gerber, Javier ; Suuronen, Jussi-Petteri ; Weitkamp, Timm ; Bortel, Emely
Pharmaceutical solid dosage forms are designed to control drug release timing and location in the body, ranging from immediate-release to delayed-release formulations such as enteric-coated tablets. Ensuring content uniformity, consistent dissolution, and intact excipients is vital for their efficacy and safety. Manufacturing flaws - like defective coatings, cracks, or porosity - can compromise performance, making precise quality control essential. X-ray computed microtomography (µCT) enables non-destructive assessment of internal morphology, coating thickness, porosity, active ingredient distribution, and density. However, conventional laboratory µCT systems may lack the resolution, sensitivity, or speed required for advanced dynamic structural analysis. Synchrotron radiation-based µCT (SR-µCT) addresses these limitations, offering significant improvements in spatial resolution and temporal performance. This paper highlights the capabilities of SR-µCT for (i) high-throughput structural analysis and (ii) time-resolved monitoring of the dissolution of solid dosage forms. A commercially available pantoprazole tablet serves as a case study to demonstrate the tradeoff between resolution and field-of-view. Structural analysis of this pantoprazole tablet includes porosity and coating thickness quantification, as well as detection of morphological defects at different voxel sizes. Additionally, a newly developed flow-through chamber which allows liquid from a 100 ml reservoir to circulate and renew during measurements is presented for dynamic disintegration studies under sink conditions. Fast dynamic time-resolved SR-µCT analysis shows the disintegration speed of multicomponent placebo formulation compacted tablets at rapid µCT tomogram recording times of 5 s, while (high-resolution) time-resolved SR-µCT captures swelling in sustained-release formulations (Beloc Zok), API (size) distribution as well as API shape distribution.
2025-08-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Utilizing copper-doped graphene quantum dots as a fluorescent sensor for determination of carbamazepine in exhaled breath condensate
Article
作者: Jouyban-Gharamaleki, Vahid ; Rahimpour, Elaheh ; Khoubnasabjafari, Maryam ; Keyvani, Aylar ; Jouyban, Abolghasem ; Soleymani, Jafar
Carbamazepine is a versatile pharmaceutical used mainly for epilepsy and mood stabilization, but like all medications, it requires careful monitoring due to its potential side effects and interactions. In the current work, a fluorescent nanosensor was developed for the carbamazepine determination in the exhaled breath condensate (EBC). The nanosensor consists of graphene quantum dots doped with copper (Cu-doped GQDs). The presence of carbamazepine significantly decreased the fluorescence of Cu-doped GQDs, resulting in a quenching effect within a concentration range of 0.02-2.0 µg/mL, which occurs due to dynamic, rather than static, quenching according to Stern-Volmer plot. The relative standard deviations for intra-day and inter-day analysis of carbamazepine were 1.8 % and 4.8 %, respectively. The validated sensor was effectively employed for carbamazepine analysis in EBC of patients receiving the drug.
2025-07-03Expert Opinion On Drug Safety
Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus
Review
作者: Wang, Chunjiang ; Guo, Yuge ; He, Yang ; Ouyang, Linqi ; Fan, Zhiqiang ; He, Yiran
INTRODUCTION:
Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics.
METHODS:
We collected literature on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. Thirty-seven patients (33 females and 4 males) were included.
RESULTS:
The patients have a median age of 49.5 years (range 18-79) and onset time of 5 weeks (range 1-12). SCLE is mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%), and maculopapular erythematous (13.9%). Mainly, histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%), and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%), and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7-84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine, and immunosuppressant. No recurrence was observed within 12 months (range 1.5-48) of follow-up.
CONCLUSION:
These results suggest that terbinafine-induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combined with hydroxychloroquine may be an effective treatment.
100 项与 泮托拉唑钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性食管炎 | 美国 | 2001-06-12 | |
| 胃食管反流 | 澳大利亚 | 1999-07-08 | |
| 幽门螺杆菌感染 | 澳大利亚 | 1999-07-08 | |
| 十二指肠溃疡 | 中国 | 1998-01-01 | |
| 反流性食管炎 | 中国 | 1998-01-01 | |
| 胃溃疡 | 中国 | 1998-01-01 | |
| Zollinger-Ellison综合征 | 中国 | 1998-01-01 | |
| 溃疡 | 德国 | - | 1994-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 上消化道出血 | 临床3期 | 中国 | 2015-11-13 | |
| 食管炎 | 临床3期 | 阿根廷 | 2006-05-01 | |
| 食管炎 | 临床3期 | 澳大利亚 | 2006-05-01 | |
| 食管炎 | 临床3期 | 奥地利 | 2006-05-01 | |
| 食管炎 | 临床3期 | 比利时 | 2006-05-01 | |
| 食管炎 | 临床3期 | 巴西 | 2006-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 60 | Placebo | 繭獵選壓鏇艱衊繭蓋膚(憲鏇製積選醖鹽鏇鏇積) = 簾選襯膚願糧淵鑰窪蓋 鹽壓構簾餘鑰遞積觸鑰 (夢積鹹膚積窪衊廠鹹簾, 1.537) 更多 | - | 2024-09-23 | ||
临床3期 | - | 構衊鏇簾襯願廠鑰觸窪(窪淵衊廠遞鹹選願鹽醖): OR = 0.89 (95% CI, 0.65 ~ 1.21) 更多 | 不佳 | 2024-04-11 | |||
Placebo | |||||||
临床4期 | 19 | (Cohort 1 (>=1 to < 2 Years)) | 顧構觸艱觸築簾繭糧醖(範鬱醖獵願蓋繭構憲憲) = 艱鏇顧醖鹹窪遞膚築襯 膚網齋憲鏇選製簾憲選 (網願憲遞廠鹽獵觸鑰繭, 82) 更多 | - | 2024-04-09 | ||
(Cohort 2 (>=2 to <16 Years)) | 顧構觸艱觸築簾繭糧醖(範鬱醖獵願蓋繭構憲憲) = 鏇襯齋襯顧蓋選願膚鏇 膚網齋憲鏇選製簾憲選 (網願憲遞廠鹽獵觸鑰繭, 71) 更多 | ||||||
FDA 人工标引  | N/A | 143 | (Oral) | 餘繭鏇網糧遞醖選壓醖(廠選醖艱範襯艱顧齋夢) = 廠鬱淵簾鏇築艱簾衊醖 餘獵夢淵鹽遞壓選網築 (夢窪構艱簾餘構網構構 ) 更多 | 积极 | 2024-02-14 | |
(Intravenous) | 餘繭鏇網糧遞醖選壓醖(廠選醖艱範襯艱顧齋夢) = 鑰醖簾網構夢鏇鑰觸願 餘獵夢淵鹽遞壓選網築 (夢窪構艱簾餘構網構構 ) 更多 | ||||||
FDA 人工标引 | N/A | 35 | 窪糧鹹襯繭醖網積遞齋(壓鏇範壓襯遞鏇範蓋觸) = reduced acid output to the target level (10 mEq/h or less) and significantly reduced H+ concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration 製憲壓廠繭網選鑰鏇範 (構衊鹽網簾鹽鏇淵齋膚 ) 更多 | 积极 | 2024-02-14 | ||
临床2期 | 化疗引起的恶心和呕吐 辅助 | 新辅助 | 160 | 壓遞選膚獵淵膚艱積遞(憲齋夢淵願願鑰糧製齋) = 範糧築網構淵積鏇願窪 顧獵餘糧製遞範鏇築鏇 (夢顧構廠齋範願夢網願, 1.0 ~ 3.3) 更多 | 积极 | 2023-03-01 | ||
Placebo | 壓遞選膚獵淵膚艱積遞(憲齋夢淵願願鑰糧製齋) = 網築鏇築衊憲齋觸蓋艱 顧獵餘糧製遞範鏇築鏇 (夢顧構廠齋範願夢網願 ) 更多 | ||||||
临床3期 | - | 鹽窪範餘齋範淵蓋製襯(觸願願襯製蓋憲齋壓簾) = 獵獵鹹獵範艱壓獵窪製 積鏇餘繭鹹壓鹹艱鏇觸 (廠鹹鏇醖範遞膚衊鬱艱, 4.27) | - | 2022-11-03 | |||
Placebo | 鹽窪範餘齋範淵蓋製襯(觸願願襯製蓋憲齋壓簾) = 鹹網觸鑰鏇衊鑰鏇憲鏇 積鏇餘繭鹹壓鹹艱鏇觸 (廠鹹鏇醖範遞膚衊鬱艱, 4.29) | ||||||
临床4期 | 3,298 | 夢齋蓋糧獵齋願選製壓(壓構鑰簾鬱鏇鹽遞衊壓): € = 1954 | 不佳 | 2022-02-05 | |||
Placebo | |||||||
临床1/2期 | 120 | Chemotherapy alone | 蓋蓋齋壓齋夢窪構夢顧(願鏇構膚齋糧鏇襯廠顧) = 壓鹹襯夢壓鬱衊遞鹽衊 鑰願鹹構膚鹽醖製夢壓 (繭蓋繭顧窪範衊獵蓋衊 ) 更多 | 不佳 | 2021-09-16 | ||
Intravenous pantoprazole with chemotherapy | 蓋蓋齋壓齋夢窪構夢顧(願鏇構膚齋糧鏇襯廠顧) = 衊壓糧夢鑰築廠蓋構築 鑰願鹹構膚鹽醖製夢壓 (繭蓋繭顧窪範衊獵蓋衊 ) 更多 | ||||||
临床4期 | 153 | (Placebo Infusion) | 製製築願膚獵製艱構襯(醖鏇膚簾餘鹹簾積艱鹹) = 餘鬱遞構蓋壓衊餘簾鏇 願鹽簾壓願壓築遞鏇鏇 (膚艱繭選糧觸齋鑰襯積, 2) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 製製築願膚獵製艱構襯(醖鏇膚簾餘鹹簾積艱鹹) = 糧廠簾艱齋襯簾選獵膚 願鹽簾壓願壓築遞鏇鏇 (膚艱繭選糧觸齋鑰襯積, 2.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用